Express vs Jazz Pharmaceuticals

Both Express Scripts and Jazz Pharmaceuticals are well-known companies in the pharmaceutical industry, however, they cater to different markets. Express Scripts focuses on pharmacy benefit management services, while Jazz Pharmaceuticals specializes in developing and commercializing innovative treatments for various diseases. Both companies have had fluctuations in their stock prices over the years, with investors closely monitoring their performance. Understanding the dynamics of these two stocks is crucial for making informed investment decisions in the pharmaceutical sector.

Express or Jazz Pharmaceuticals?

When comparing Express and Jazz Pharmaceuticals, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Express and Jazz Pharmaceuticals.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Express has a dividend yield of -%, while Jazz Pharmaceuticals has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Express reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Jazz Pharmaceuticals reports a 5-year dividend growth of 0.00% year and a payout ratio of 28.43%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Express P/E ratio at 0.02 and Jazz Pharmaceuticals's P/E ratio at 18.67. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Express P/B ratio is 0.02 while Jazz Pharmaceuticals's P/B ratio is 1.96.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Express has seen a 5-year revenue growth of 0.00%, while Jazz Pharmaceuticals's is 0.92%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Express's ROE at 81.57% and Jazz Pharmaceuticals's ROE at 10.76%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $0.35 for Express and $111.04 for Jazz Pharmaceuticals. Over the past year, Express's prices ranged from $0.35 to $17.84, with a yearly change of 4997.14%. Jazz Pharmaceuticals's prices fluctuated between $99.06 and $137.39, with a yearly change of 38.69%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.